Why the study?
Data are conflicting regarding the safety and efficacy of IV thrombolysis in patients with acute ischemic stroke who are receiving dual antiplatelet pretreatment.
Does dual antiplatelet pretreatment increase the risk of symptomatic intracranial hemorrhage or mortality in patients with acute ischemic stroke treated with IV thrombolysis?
Does dual antiplatelet pretreatment increase the risk of symptomatic intracranial hemorrhage or mortality in patients with acute ischemic stroke treated with IV thrombolysis?
Dual antiplatelet pretreatment prior to IV thrombolysis for acute ischemic stroke does not appear to independently increase the risk of symptomatic intracranial hemorrhage or mortality after adjusting for confounders.
Authors
No takes yet. Share an insight, caveat, or question.
Adjusted analyses support IVT safety despite DAPP; extends observational data without changing practice yet.
Malhotra et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: